Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim Biomarker Validation in Parkinson's Disease
NCT05677633Phase 1Completed
- Sponsor
- University of Nebraska
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sargramostim in Parkinson's disease (PD), sponsored by University of Nebraska. Primary endpoint: Change in incidence of adverse events over time. Started Jan 2023; status: completed.
02
Drugs
sargramostim
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05677633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677633.